Last reviewed · How we verify
Liposomal Bupivacaine 13.3 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Liposomal Bupivacaine 13.3 (Liposomal Bupivacaine 13.3) — Pacira Pharmaceuticals, Inc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Liposomal Bupivacaine 13.3 TARGET | Liposomal Bupivacaine 13.3 | Pacira Pharmaceuticals, Inc | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Liposomal Bupivacaine 13.3 CI watch — RSS
- Liposomal Bupivacaine 13.3 CI watch — Atom
- Liposomal Bupivacaine 13.3 CI watch — JSON
- Liposomal Bupivacaine 13.3 alone — RSS
Cite this brief
Drug Landscape (2026). Liposomal Bupivacaine 13.3 — Competitive Intelligence Brief. https://druglandscape.com/ci/liposomal-bupivacaine-13-3. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab